Secondary use of existing data refers to the practice of analyzing data that was collected for a different purpose than the current research question. This approach is becoming increasingly popular in real-world research because of the large amounts of data that are available through various sources, such as electronic health records, administrative databases, and social media.
In many cases, secondary data analysis can provide valuable insights and answer research questions that would otherwise be difficult or impossible to answer with primary data collection. For example, researchers can use existing data to study disease trends, evaluate the effectiveness of health interventions, and identify risk factors for various health outcomes.
Secondary data analysis can also be more cost-effective than primary data collection, as the data has already been collected and often comes at a lower cost than conducting a new study. Additionally, secondary data analysis can allow researchers to study topics that may not have been feasible to study with primary data collection due to ethical or practical limitations.
However, there are also potential limitations to secondary data analysis, such as the lack of control over the quality and accuracy of the data, and the potential for biases and confounding factors that were not accounted for in the original data collection. Therefore, researchers must carefully evaluate the suitability of existing data for their research question and take steps to address any limitations or potential biases in the data.
Share this story...
Real World Evidence (RWE) 101 – Registry vs Registry-Based Study
RWE 101 - Registry vs Registry-Based Study In the context of real-world evidence, a registry is a collection of data on a particular disease, medical condition, or [...]
Real World Evidence (RWE) 101 – Pregnancy Registries
RWE 101 - Pregnancy Registries A pregnancy registry is a type of real-world evidence collection system that collects data from pregnant women who have been exposed to [...]
Real World Evidence (RWE) 101 – Diversity
RWE 101 - Diversity Diversity in the context of real-world research refers to the inclusion of individuals from different backgrounds, including but not limited to race, ethnicity, gender, [...]
Real World Evidence (RWE) 101 – The Patient Voice
RWE 101 - The Patient Voice The patient voice refers to the perspectives, opinions, and experiences of patients and their families or caregivers in the context of [...]
Real World Evidence (RWE) 101 – ISPE GPP
RWE 101 - ISPE GPP The International Society of Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practices (GPP) provides guidance for the conduct and reporting of pharmacoepidemiologic studies. The key [...]
Real World Evidence (RWE) 101 – EMA Good Pharmacovigilance Practices (GVPs)
RWE 101 - EMA Good Pharmacovigilance Practices (GVPs) The European Medicines Agency's (EMA) Good Pharmacovigilance Practices (GVPs) provide a framework for the monitoring and reporting of adverse drug [...]







